Supply Chain

 The FDA has so far approved 44 percent fewer new drugs in 2018 than a year prior, according to a report from Fitch Ratings.

The FDA has exempted some genetic health risk assessments from the agency's premarket notification — or 510(k) — requirements, effective June 5.

The price of estrogen replacement therapies used to treat menopause symptoms doubled between 2014 and 2018, according to an analysis from GoodRx.

The FDA alerted healthcare providers June 4 about five more deaths of patients using two brands of fluid-filled intragastric balloon systems to treat obesity.

Drugmaker Hospira issued a nationwide recall for two lots of its injectable opioid overdose antidote Naloxone over the potential presence of embedded and loose particulate matter on the syringe plunger.

The growing risks, costs, and frustrations caused by OR supply chain inefficiencies now pose more serious consequences than ever before.

The FDA plans to modernize its Center for Drug Evaluation and Research's Office of New Drugs, which is responsible for reviewing and approving new medications.

Inefficient inventory and supply chain management processes can be a significant money drain for ASCs, which already function on tight margins.

The Durham (N.C.) Veterans Affairs Medical center purchased nearly $1.4 million in supplies in 2014 that were sent to a storage facility and never unpacked, according to Stars and Stripes.

A decade ago, the Institute for Healthcare Improvement coined the term the Triple Aim and outlined its respective components.